Concentration of alpha-fetoprotein (AFP) may be increased in some type of lung cancer. In the study concentration of AFP was evaluated in serum and broncho-alveolar lavage fluid (BALF) in patients with lung cancer. The values of concentration were compared with results obtained from patients with other diseases of the respiratory tract. Examinations were performed in 14 patients with lung cancer, 12 with sarcoidosis, 23 with chronic obstructive bronchitis and 16 with acute bronchitis. Liver pathology was excluded according to biochemical analytical tests. In all patients bronchofibroscopy was performed and BALF was obtained in routine way. Concentration of AFP in serum and BALF was determined by immuno-assay technique. In performed examinations non significant increase of AFP concentration was determined in serum and BALF of patients with lung cancer. However, obtained values were increased twice than in patients with acute bronchitis. Moreover, it was noticed that in patients with chronic obstructive bronchitis the AFP concentration was the highest, especially in the group treated by steroids. The study indicates that evaluation of AFP concentration is out of value in diagnosis and differentiation of lung cancer. It seems to be necessary to continue the examinations for explanation a role of steroids in inflammatory process and increase of AFP concentration.
Download full-text PDF |
Source |
---|
Cancer Nurs
January 2025
Author Affiliations: Departments of Physiotherapy (Drs Heredia Ciuró, Martín Núñez, Navas Otero, Calvache Mateo, Torres Sánchez, and Valenza) and Nursing (Dr Granados Santiago), Faculty of Health Sciences, University of Granada, Granada, Spain.
Background: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness.
View Article and Find Full Text PDFCurr Oncol Rep
January 2025
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.
Purpose Of Review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy.
View Article and Find Full Text PDFCancer Metastasis Rev
January 2025
Saliva and Liquid Biopsy Translational Laboratory, Institute for Biomedicine and Glycomics (IBG), Griffith University, Brisbane, 4111, Australia.
CT chest scans are commonly performed worldwide, either in routine clinical practice for a wide range of indications or as part of lung cancer screening programs. Many of these scans detect lung nodules, which are small, rounded opacities measuring 8-30 mm. While the concern about nodules is that they may represent early lung cancer, in screening programs, only 1% of such nodules turn out to be cancer.
View Article and Find Full Text PDFSurg Today
January 2025
Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Purpose: The pattern of lymph node metastasis and the appropriate extent of lymph node dissection in splenic flexure colon cancer remain unclear. This study aimed to describe the clinical characteristics, lymph node metastasis patterns, and oncological outcomes of patients with splenic flexure colon cancer.
Methods: The data of patients with splenic flexure cancer diagnosed with pathological stages I-III were extracted from a hospital database.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Non-small cell lung cancer (NSCLC) is a widespread highly malignant type of lung cancer. Conventional chemotherapeutic drugs may be accompanied by both drug resistance and serious side effects in patients. Therefore, safer and more effective medications are urgently needed for the treatment of NSCLC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!